(NASDAQ: CSBR) Champions Oncology's forecast annual revenue growth rate of 13.18% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 246.57%, and while it is forecast to beat the US market's average forecast revenue growth rate of 12.87%.
Champions Oncology's revenue in 2024 is $49,224,000.On average, 1 Wall Street analysts forecast CSBR's revenue for 2024 to be $757,308,760, with the lowest CSBR revenue forecast at $757,308,760, and the highest CSBR revenue forecast at $757,308,760.
In 2025, CSBR is forecast to generate $850,969,814 in revenue, with the lowest revenue forecast at $850,969,814 and the highest revenue forecast at $850,969,814.